A diverse panel of clinical acinetobacter baumannii for research and development

Authors

Madeline R. Galac, Walter Reed Army Institute of Research
Erik Snesrud, Walter Reed Army Institute of Research
Francois Lebreton, Walter Reed Army Institute of Research
Jason Stam, Walter Reed Army Institute of Research
Michael Julius, Walter Reed Army Institute of Research
Ana C. Ong, Walter Reed Army Institute of Research
Rosslyn Maybank, Walter Reed Army Institute of Research
Anthony R. Jones, Armed Forces Research Institute of Medical Sciences, Thailand
Yoon I. Kwak, Walter Reed Army Institute of Research
Kate Hinkle, Rochester Regional Health
Paige E. Waterman, Walter Reed Army Institute of Research
Emil P. Lesho, Rochester Regional HealthFollow
Jason W. Bennett, Walter Reed Army Institute of Research
Patrick Mc Gann, Walter Reed Army Institute of Research

Department

Infectious Diseases

Document Type

Article

Publication Title

Antimicrobial Agents and Chemotherapy

Abstract

Over the past two decades, Acinetobacter baumannii has emerged as a leading cause of nosocomial infections worldwide. Of particular concern are panresistant strains, leading the World Health Organization (WHO) to designate carbapenem-resistant A. baumannii as a priority 1 (critical) pathogen for research and development of new antibiotics. A key component in supporting this effort is accessibility to diverse and clinically relevant strains for testing. Here, we describe a panel of 100 diverse A. baumannii strains for use in this endeavor. Whole-genome sequencing was performed on 3,505 A. baumannii isolates housed at the Multidrug-Resistant Organism Repository and Surveillance Network. Isolates were cultured from clinical samples at health care facilities around the world between 2001 and 2017. Core-genome multilocus sequence typing and high-resolution single nucleotide polymorphism (SNP)-based phylogenetic analyses were used to select a final panel of 100 strains that captured the genetic diversity of the collection. Comprehensive antibiotic susceptibility testing was also performed on all 100 isolates using 14 clinically relevant antibiotics. The final 100-strain diversity panel contained representative strains from 70 different traditional Pasteur scheme multilocus sequence types, including major epidemic clones. This diversity was also reflected in antibiotic susceptibility and antimicrobial resistance (AMR) gene content, with phenotypes ranging from pansensitive to panresistant, and over 100 distinct AMR gene alleles identified from 32 gene families. This panel provides the most diverse and comprehensive set of A. baumannii strains for use in developing solutions for combating antibiotic resistance. The panel and all available metadata, including genome sequences, will be available to industry and academic institutions and federal and other laboratories free of charge.

DOI

10.1128/AAC.00840-20

Volume

64

Issue

10

Publication Date

10-1-2020

Recommended Citation

Galac, M., Snesrud, E., Lebreton, F., Stam, J., Julius, M., Ong, A., Maybank, R., Jones, A., Kwak, Y., Hinkle, K., Waterman, P., Lesho, E. P., Bennett, J., & Gann, P. (2020). A diverse panel of clinical acinetobacter baumannii for research and development. Antimicrobial Agents and Chemotherapy, 64 (10) https://doi.org/10.1128/AAC.00840-20